Application of neo-bioscore staging to predict the benefit of pertuzumab in HER2 positive early breast cancer

被引：0
|
作者：
Sanchez Escudero, L. [1 ]
Morales Pancorbo, D. [2 ]
Bayo, J. [3 ]
Aragon Manrique, I. [3 ]
机构：
[1] Hosp Juan Ramon Jimenez, Oncol, Huelva, Spain
[2] Hosp Juan Ramon Jimenez, Med, Huelva, Spain
[3] Hosp Juan Ramon Jimenez, Oncol Med, Huelva, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
197P
引用
收藏
页码：S442 / S443
页数：2
相关论文
共 50 条
  • [21] Dual HER2 blockade in adjuvant and neoadjuvant treatment of HER2-positive breast cancer: the role of pertuzumab
    Duchnowska, Renata
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 43 - 47
  • [22] Effectiveness of the trastuzumab-pertuzumab dual block in neoadjuvance of HER2 positive breast cancer
    Ruiz Pena, Ana Cristina
    Dominguez Eguizabal, Beatriz
    Mann Alfaro, Susana
    Fernandez Garcia, Cristina
    Laguna Olmos, Mariano
    Puente Martinez, Maria Jose
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (04) : 721 - 729
  • [23] Efficacy and safety of pertuzumab for HER2 positive metastatic breast cancer: a single institution experience
    Hara, Fumikata
    Aogi, Kenjiro
    Takashima, Seiki
    ANNALS OF ONCOLOGY, 2015, 26 : 141 - 141
  • [24] Pertuzumab in HER2-positive early breast cancer: current use and perspectives
    Eiger, Daniel
    Ponde, Noam Falbel
    de Azambuja, Evandro
    FUTURE ONCOLOGY, 2019, 15 (16) : 1823 - 1844
  • [25] Alternative targeted therapy for early Her2 positive breast cancer
    Harvey, Sandra L.
    Khasraw, Mustafa
    GLAND SURGERY, 2013, 2 (01) : 42 - 45
  • [26] Analysis of biomarkers in a pilot study of pertuzumab, trastuzumab and eribulin for advanced HER2 positive breast cancer
    Tono, Yasutaka
    Ishihara, Mikiya
    Miyahara, Yoshihiro
    Ikeda, Hiroaki
    Shiku, Hiroshi
    Shiraishi, Taizo
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Prediction of response to trasutuzumab/pertuzumab/taxane therapy by microRNA in HER2 positive advanced breast cancer
    Kawachi, A.
    Shimomura, A.
    Matsuzaki, J.
    Kawauchi, J.
    Takizawa, S.
    Sakamoto, H.
    Shimizu, C.
    Tamura, K.
    Ochiya, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
    Rayson, Daniel
    Gandhi, Sonal
    Joy, Anil A.
    Brezden-Masley, Christine
    Gelmon, Karen A.
    Sehdev, Sandeep
    Cescon, David
    Chia, Stephen
    CURRENT ONCOLOGY, 2022, 29 (12) : 9891 - 9895
  • [29] Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer
    Overmoyer, Beth
    Regan, Meredith
    Hu, Jiani
    Nakhlis, Faina
    Dominici, Laura
    Lin, Nancy U.
    Freedman, Rachel
    Morganstern, Daniel E.
    Partridge, Ann H.
    Schlosnagle, Emily J.
    Hirshfield-Bartek, Judi
    Bellon, Jennifer
    Morikawa, Aki
    Harrison, Beth T.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
  • [30] Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients
    Stephanie Gu
    Stephen Dusza
    Elizabeth Quigley
    Helen Haliasos
    Alina Markova
    Michael Marchetti
    Andrea P. Moy
    Chau Dang
    Shanu Modi
    Diana Lake
    Sarah Noor
    Mario E. Lacouture
    Breast Cancer Research and Treatment, 2024, 203 : 271 - 280
12345